1 June 2023

IAMA Therapeutics to Present at Upcoming BIO International Convention

GENOA, Italy, June 1, 2023 – IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in […]
31 May 2023

Business Wire – 31/05/2023

IAMA Therapeutics Announces Addition of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to Scientific Advisory Board
13 January 2023

Business Wire – 12/01/2023

IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
26 July 2022

Business Wire – 27/07/22

IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
29 June 2022

Business Wire – 29/06/22

IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
24 May 2022

Business Wire – 24/05/22

IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry
31 March 2022

Business Wire – 31/03/22

IAMA Therapeutics Announces Formation of Scientific Advisory Board
11 February 2022

Business Wire – 29/03/22

IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery